Pulmonary Arterial Hypertension (PAH)

Antigen pharmaceuticals - a part of Goldshield Critical Care Europe has signed an exclusive distribution agreement in October 2000 with United Therapeutics Inc. a biotechnology company based in USA to market a new chemical entity Treprostinil in UK and Ireland. This product is already licensed for the treatment of a life threatening condition pulmonary arterial hypertension in USA, Canada, Israel, France, Germany, Scandinavia, Italy and is currently under review in UK, Spain and Ireland.

Goldshield Critical Care Europe's expertise in the secondary care sector built on an established rapport with specialist clinicians, nurses and pharmacists and supported by increased marketing resources and infrastructure made us the ideal partner for United Therapeutics in the UK and Ireland.